The latest price target for Zymeworks (NASDAQ:ZYME) was reported by Truist Securities on December 17, 2025. The analyst firm set a price target for $40.00 expecting ZYME to rise to within 12 months (a possible 56.31% upside). 19 analyst firms have reported ratings in the last year.

The latest analyst rating for Zymeworks (NASDAQ:ZYME) was provided by Truist Securities, and Zymeworks initiated their buy rating.

The last upgrade for Zymeworks Inc happened on December 12, 2025 when Wells Fargo raised their price target to $33. Wells Fargo previously had an equal-weight for Zymeworks Inc.

The last downgrade for Zymeworks Inc happened on November 1, 2024 when Wells Fargo changed their price target from $12 to $12 for Zymeworks Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Zymeworks, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Zymeworks was filed on December 17, 2025 so you should expect the next rating to be made available sometime around December 17, 2026.

While ratings are subjective and will change, the latest Zymeworks (ZYME) rating was a initiated with a price target of $0.00 to $40.00. The current price Zymeworks (ZYME) is trading at is $25.59, which is within the analyst’s predicted range.